EVOLUS, INC. Amortization of Intangible Assets
EVOLUS, INC. (EOLS) reported Amortization of Intangible Assets of $1.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-05
- EVOLUS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $1.88M, a 25.42% increase year-over-year.
- EVOLUS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $1.89M, a 48.47% increase year-over-year.
- EVOLUS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $1.82M, a 84.43% increase year-over-year.
- EVOLUS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $1.68M, a 109.09% increase year-over-year.
- EVOLUS, INC. amortization of intangible assets for fiscal 2025 was $6.27M, a 52.85% increase from fiscal 2024.
- EVOLUS, INC. amortization of intangible assets for fiscal 2024 was $4.10M, a 0.79% increase from fiscal 2023.
- EVOLUS, INC. amortization of intangible assets for fiscal 2023 was $4.07M, a 21.55% increase from fiscal 2022.
- EVOLUS, INC. amortization of intangible assets for fiscal 2022 was $3.35M, a 36.85% decline from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.88M 10-Q · filed 2026-08-05 | $3.77M 10-Q · filed 2026-08-05 | $5.59M derived: sum of 3 quarters · filed 2026-08-05 | $7.27M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $1.89M 10-Q · filed 2026-05-04 | $3.72M derived: sum of 2 quarters · filed 2026-05-04 | $5.40M derived: sum of 3 quarters · filed 2026-05-04 | $6.89M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.50M derived: sum of 2 quarters · filed 2026-03-03 | $5.00M derived: sum of 3 quarters · filed 2026-08-05 | $6.27M 10-K · filed 2026-03-03 | ||
| 2025-09-30 | $1.68M 10-Q · filed 2025-11-05 | $3.17M derived: sum of 2 quarters · filed 2026-08-05 | $4.45M 10-Q · filed 2025-11-05 | $5.44M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $1.50M 10-Q · filed 2026-08-05 | $2.77M 10-Q · filed 2026-08-05 | $3.76M derived: sum of 3 quarters · filed 2026-08-05 | $4.56M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $1.27M 10-Q · filed 2026-05-04 | $2.26M derived: sum of 2 quarters · filed 2026-05-04 | $3.07M derived: sum of 3 quarters · filed 2026-05-04 | $4.22M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $989.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.79M derived: sum of 2 quarters · filed 2026-03-03 | $2.95M derived: sum of 3 quarters · filed 2026-03-03 | $4.10M 10-K · filed 2026-03-03 | ||
| 2024-09-30 | $803.00K 10-Q · filed 2025-11-05 | $1.96M derived: sum of 2 quarters · filed 2025-11-05 | $3.12M 10-Q · filed 2025-11-05 | $4.18M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $1.16M 10-Q · filed 2025-08-05 | $2.31M 10-Q · filed 2025-08-05 | $3.38M derived: sum of 3 quarters · filed 2026-03-03 | $4.43M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $1.15M 10-Q · filed 2025-05-07 | $2.22M derived: sum of 2 quarters · filed 2026-03-03 | $3.27M derived: sum of 3 quarters · filed 2026-03-03 | $4.27M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.12M derived: sum of 2 quarters · filed 2026-03-03 | $3.12M derived: sum of 3 quarters · filed 2026-03-03 | $4.07M 10-K · filed 2026-03-03 | ||
| 2023-09-30 | $1.05M 10-Q · filed 2024-11-06 | $2.05M derived: sum of 2 quarters · filed 2024-11-06 | $3.00M 10-Q · filed 2024-11-06 | $3.90M derived: sum of 4 quarters · filed 2025-03-04 | ||
| 2023-06-30 | $997.00K 10-Q · filed 2024-07-31 | $1.95M 10-Q · filed 2024-07-31 | $2.85M derived: sum of 3 quarters · filed 2025-03-04 | $3.69M derived: sum of 4 quarters · filed 2025-03-04 | ||
| 2023-03-31 | $955.00K 10-Q · filed 2024-05-07 | $1.85M derived: sum of 2 quarters · filed 2025-03-04 | $2.69M derived: sum of 3 quarters · filed 2025-03-04 | $3.46M derived: sum of 4 quarters · filed 2025-03-04 | ||
| 2022-12-31 | $896.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $1.73M derived: sum of 2 quarters · filed 2025-03-04 | $2.51M derived: sum of 3 quarters · filed 2025-03-04 | $3.35M 10-K · filed 2025-03-04 | ||
| 2022-09-30 | $838.00K 10-Q · filed 2023-11-07 | $1.61M derived: sum of 2 quarters · filed 2023-11-07 | $2.45M 10-Q · filed 2023-11-07 | $3.30M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $773.00K 10-Q · filed 2023-08-02 | $1.62M 10-Q · filed 2023-08-02 | $2.46M derived: sum of 3 quarters · filed 2023-08-02 | $3.30M derived: sum of 4 quarters · filed 2023-08-02 | ||
| 2022-03-31 | $843.00K 10-Q · filed 2023-05-09 | $1.69M derived: sum of 2 quarters · filed 2023-05-09 | $2.53M derived: sum of 3 quarters · filed 2023-05-09 | $4.20M derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $842.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $1.69M derived: sum of 2 quarters · filed 2023-03-08 | $3.35M derived: sum of 3 quarters · filed 2023-03-08 | $5.30M 10-K · filed 2023-03-08 | ||
| 2021-09-30 | $843.00K 10-Q · filed 2022-11-08 | $2.51M derived: sum of 2 quarters · filed 2022-11-08 | $4.46M 10-Q · filed 2022-11-08 | $3.29M derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $1.67M 10-Q · filed 2022-08-02 | $3.62M 10-Q · filed 2022-08-02 | $2.44M derived: sum of 3 quarters · filed 2022-08-02 | $4.11M derived: sum of 4 quarters · filed 2022-08-02 | ||
| 2021-03-31 | $1.95M 10-Q · filed 2022-05-10 | $775.00K derived: sum of 2 quarters · filed 2022-05-10 | $2.44M derived: sum of 3 quarters · filed 2022-05-10 | $3.98M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $486.00K derived: sum of 2 quarters · filed 2022-03-03 | $2.03M derived: sum of 3 quarters · filed 2022-03-03 | $3.63M 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $1.66M 10-Q · filed 2021-11-02 | $3.21M derived: sum of 2 quarters · filed 2021-11-02 | $4.81M 10-Q · filed 2021-11-02 | $6.14M derived: sum of 4 quarters · filed 2021-11-02 | ||
| 2020-06-30 | $1.55M 10-Q · filed 2021-08-04 | $3.15M 10-Q · filed 2021-08-04 | $4.48M derived: sum of 3 quarters · filed 2021-08-04 | $5.59M derived: sum of 4 quarters · filed 2021-08-04 | ||
| 2020-03-31 | $1.60M 10-Q · filed 2021-05-12 | $2.93M derived: sum of 2 quarters · filed 2021-05-12 | $4.05M derived: sum of 3 quarters · filed 2021-05-12 | $4.97M derived: sum of 4 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $2.45M derived: sum of 2 quarters · filed 2021-03-25 | $3.37M derived: sum of 3 quarters · filed 2021-03-25 | $3.85M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $1.11M 10-Q · filed 2020-10-29 | $2.04M derived: sum of 2 quarters · filed 2020-10-29 | $2.52M 10-Q · filed 2020-10-29 | |||
| 2019-06-30 | $923.00K 10-Q · filed 2020-08-10 | $900.00K 10-Q · filed 2019-08-12 | $1.41M 10-Q · filed 2020-08-10 | $1.40M 10-Q · filed 2019-08-12 | ||
| 2019-03-31 | $484.00K 10-Q · filed 2020-05-11 | |||||
| 2018-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |